BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/20/2017 4:03:35 AM | Browse: 1398 | Download: 2957
 |
Received |
|
2017-08-18 00:18 |
|
Peer-Review Started |
|
2017-08-18 08:19 |
|
First Decision by Editorial Office Director |
|
2017-08-29 18:02 |
|
Return for Revision |
|
2017-09-03 11:55 |
|
Revised |
|
2017-09-18 10:49 |
|
Publication Fee Transferred |
|
2017-10-31 11:33 |
|
Second Decision by Editor |
|
2017-10-11 07:46 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2017-10-17 20:09 |
|
Articles in Press |
|
2017-10-17 20:09 |
|
Edit the Manuscript by Language Editor |
|
2017-11-06 12:35 |
|
Typeset the Manuscript |
|
2017-11-13 01:39 |
|
Publish the Manuscript Online |
|
2017-11-20 04:03 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017.Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zi-Han Zhang, Qing-Xin Liu, Wen Zhang, Jing-Qin Ma, Jian-Hua Wang, Jian-Jun Luo, Ling-Xiao Liu and Zhi-Ping Yan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Advanced and Appropriate Technique Generalization from Shanghai Health and Family Planning Committee |
2013SY060 |
| Scientific program from Shanghai Municipal Heath Bureau |
20124188 |
|
| Corresponding Author |
Jian-Jun Luo, MD, Doctor, Doctor, Research Associate, Research Scientist, Department of Interventional Radiology, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, China, Shangai 200032, China. zsluojianjun@126.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Endovascular brachytherapy; Main portal vein tumor thrombus; Sorafenib |
| Core Tip |
As portal vein tumor thrombus occurs in a high proportion of hepatocellular carcinoma patients and no standard treatment has been established, we aimed to evaluate the effect of endovascular brachytherapy (EVBT) combined with stent placement, transarterial chemoembolization (TACE), and sorafenib and compared this strategy with TACE plus sorafenib alone. The results of our study revealed that EVBT along with stent placement, TACE, and sorafenib is a safe and effective palliative treatment option for main portal vein tumor thrombus. |
| Publish Date |
2017-11-20 04:03 |
| Citation |
Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol 2017; 23(43): 7735-7745
|
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i43/7735.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i43.7735 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
